Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00169559 · ClinicalTrials.gov registry record · Phase 2
Dyslipidemia Study Investigating The Increase In "Good Cholesterol"
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
NCT00169559 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 250 participants.
The verdict
NCT00169559, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
Study Summary
An eight week comparison of the investigational drug GW590735, placebo, and the marketed drug fenofibrate intended to increase the levels of "good cholesterol" and decrease levels of "bad cholesterol" in healthy patients with low levels of good cholesterol and high levels of bad cholesterol.
Interventions
- DRUG fenofibrate
- DRUG GW590735
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2003-11 |
| Est. Completion | 2005-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00169559
The ClinicalTrials.gov registry entry for NCT00169559 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which fenofibrate is the first listed.
NCT00169559 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00169559 about?
NCT00169559 is a clinical study titled "Dyslipidemia Study Investigating The Increase In "Good Cholesterol"". An eight week comparison of the investigational drug GW590735, placebo, and the marketed drug fenofibrate intended to increase the levels of "good cholesterol" and decrease levels of "bad cholesterol" in healthy patients with low levels of good cholesterol and high levels of bad cholesterol.
What is the current status of trial NCT00169559?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2003-11. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00169559?
The interventions under investigation include: fenofibrate (DRUG), GW590735 (DRUG).
Who is sponsoring clinical trial NCT00169559?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.